Medical Boards Draw Hard Line Against Independent AI Licensing as Autonomous Prescription Systems Face Scrutiny
The Federation of State Medical Boards rejects separate licensing pathways for AI practitioners, insisting physicians remain accountable even as states experiment with autonomous clinical systems.
As artificial intelligence systems advance toward autonomous clinical decision-making, the nation's medical licensing authorities are establishing a firm regulatory boundary: AI will not be licensed to practice medicine independently, regardless of its capabilities.
In a definitive position statement, leaders of the Federation of State Medical Boards (FSMB) have declared that AI systems must remain tools governed within existing professional accountability structures rather than becoming separately licensed practitioners. The stance comes as multiple states experiment with regulatory frameworks that could fundamentally reshape how autonomous AI systems deliver healthcare.
The Regulatory Collision Course
The FSMB's position is already being tested in real-world scenarios. Utah's Office of Artificial Intelligence Policy recently approved a 12-month pilot program with health tech startup Doctronic to automate prescription renewals for 192 commonly prescribed drugs. Despite receiving state AI office approval, the program now faces scrutiny from Utah's medical board—a development that illustrates the regulatory tension FSMB leaders warn against.
The federation, which serves 69 state and territorial medical boards responsible for licensing physicians, adopted nonbinding policy guidance in 2024 establishing that professional responsibility for AI use remains with the licensed physician, not the AI system itself. This framework positions medical boards as regulators of physicians who use AI tools, not regulators of the machines themselves.
"State medical boards regulate physicians who use AI tools, not the machines themselves, and physicians remain accountable for harms caused by inappropriate AI reliance," FSMB President Humayun J. Chaudhry and Board Chair Christy Valentine Theard emphasized in their statement.
Failed Legislative Attempts Signal Growing Pressure
The push for alternative AI regulatory pathways isn't hypothetical. Both Idaho and Iowa introduced legislation in 2025-2026 proposing state licensing boards for "autonomous service providers" separate from state medical boards. While both bills ultimately failed, their introduction signals growing pressure to create regulatory frameworks that accommodate AI systems operating with minimal human oversight.
These legislative efforts reflect a fundamental question facing healthcare regulators: as AI systems become capable of independently diagnosing conditions, recommending treatments, and managing prescriptions, do traditional physician accountability models remain adequate?
Implications for Healthcare Stakeholders
For physicians, the FSMB position means clear legal and ethical accountability for all clinical decisions involving AI, regardless of the system's autonomy level. Documentation of AI use in clinical practice is becoming essential as state medical boards examine how "practice of medicine" definitions apply to AI-assisted care.
Health technology companies developing autonomous clinical systems face a fragmented regulatory landscape where medical boards retain authority over clinical decision-making even when AI operates through state innovation sandboxes or separate AI policy offices. The Doctronic case demonstrates that state AI office approval doesn't necessarily satisfy medical board requirements when clinical decisions are involved.
For patients, the FSMB framework preserves existing recourse mechanisms when medical harm occurs by maintaining clear lines of accountability with human physicians rather than shifting responsibility to AI systems.
Looking Ahead
The FSMB has formed a Workgroup on the Regulation of AI in the Practice of Medicine to address autonomous AI systems, while Washington State has established an AI Task Force examining similar regulatory questions. As workforce shortages drive interest in AI solutions that could improve access and reduce administrative burdens, the tension between innovation and accountability will likely intensify.
The regulatory path forward remains uncertain, but the FSMB's position establishes a clear starting point: AI may transform how medicine is practiced, but it won't be practicing medicine on its own license.
Sources
Companies in this article
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.